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Liver, Kidney, and Thoracic Organ Transplantation 
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ANTHONY J. DEMETRIS, M.D., ROBERT KORMOS, M.D., ASHOK JAIN, M.D., MARIO ALESSIANI, M.D., 
SHUNICHI TAKA YA, M.D., and RON SHAPIRO, M.D. 
The new immunosuppressive drug FK 506 was used from the 
outset with low doses of prednisone to treat 120 recipients of 
primary liver grafts and 20 more patients undergoing liver re-
transplantation. The patient survival rate after 2 to 8 months in 
the primary liver transplantation series is 93,3%, with original 
graft survival of 87.5%. Of the 20 patients in the hepatic re-
transplant series, 17 (85%) are living. Almost all of the surviving 
patients have good liver function. In addition 11 hearts, 2 double 
lungs, and a heart-lung have been transplanted under .FK 506, 
with survival of all 14 patients. With all of the organ systems 
so far tested, including the kidney (which has been reported else-
where), rejection usually has been controlled without additional 
drugs and with lower average steroid doses than in the past. 
Nephrotoxicity has been observed, but not to an alarming degree, 
and there has been a notable absence of hypertension. There is 
a suggestion that serum cholesterol may be lowered by FK 506, 
but this is unproved. Although the adverse reactions of FK 506 
and the immunosuppressive mechanisms resemble those of cy-
cIosporine, our preliminary observations suggest that FK 506 
may have a more advantageous therapeutic index. 
T HE NEW IMMUNOSUPPRESSIVE drug FK 506 was introduced clinically in February 1989 to replace 
cyclosporine for liver recipients who had intrac-
table rejection or drug toxicity. 1,2 In March 1989, it was 
first used as primary therapy from the time of a cadaveric 
kidney transplantation. I Between then and the beginning 
of February 1990, 140 liver and 36 kidney recipients had 
grafting procedures at the Presbyterian University and 
Children's Hospital of Pittsburgh under therapy with FK 
506 and prednisone from the time of transplantation. 3.4 
In addition 14 patients had transplantation of the heart, 
lungs, or heart-lung. The use of FK 506 for multiple-
organ transplantation, pancreatic islet cell transplantation. 
and as a device to facilitate the recent development of a 
separate Veterans Administration program will be re-
ported separately. 
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Methods 
Liver Transplantation 
The 140 patients entered into the study between July 
2, 1989 and February 4, 1990 were heterogenous in their 
indications for transplantation, degree of illness. and age. 
For analysis they were stratified into the 120 patients re-
ceiving their first liver (primary transplantation) and 20 
who were receiving their second to sixth liver (retrans-
plantation). Each main group was subdivided into adult 
(18 years or older) and pediatric (younger than 18 years) 
categories. The techniques of liver transplantation have 
been reviewed elsewhere.5 
Primary Liver Transplantation (120 Case:I~ 
There were 105 adults and 15 infants and children (Ta-
ble 1) who were given a total of 132 livers. The average 
adult age of 45 ± 11.5 (SO) years reflected both the aging 
population in our region and our nondiscriminatory pol-
icy toward older candidates; 13 (10.8%) ofthe 105 adults 
were 60 years or older. Nonalcoholic and alcoholic cir-
rhosis accounted for two thirds of the adult indications; 
9 of these patients were B-virus (HBV) carriers. The tech-
nically 'easier' cholestatic diseases, which include primary 
biliary cirrhosis and sclerosing cholangitis, were only 27% 
of the total. There was a generally high degree of illness 
and urgency as this was defined by the current United 
Network for Organ Sharing (UNOS) stratification (Table 
I): status 1, at home, functioning without nursing care; 
status 2, at home, not working and requiring professional 
nursing care; status 3, hospital bound; status 4, leu 
bound; UNOstat, ICU bound on life support. Only three 
of the adult UNOstat patients had fulminant hepatic fail-
ure. Many of the patients with chronic liver disease had 
gravitated to the desperate UNOstat condition over a long 
period while they waited for a liver to become available. 
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TABLE L Clinical Features of Primary Liver Recipients 
Feature Adult (?-18 years) Pediatric « 13 years) 
105 
116 
15 
16 
Number of patients 
Number of transplants 
Age (years)* 
Sex (M/F) 
45 ± I L5 (18 to 69) 
58/47 
4.1 ± 4.8 (0.4 to 16) 
9/6 
Disease category: No. of cases (%) 
Nonalcoholic cirrhosist 
Alcoholic cirrhosis 
Cholestatic disease 
Tumor 
Fulminant failure 
Miscellaneous 
Total 
UNOS score: No. of cases (%) 
2 
3 
4 
UNOSTAT 
42 (40) 
26 (24.7) 
28 (26.6) 
3 (2.9) 
3 (2.9) 
3 (2.9) 
105 (100) 
25 (23.8) 
39 (37.2) 
14 (13.3) 
27 (25.7) 
* Thirteen patients were ?- 60 years old; 8 were younger than 2 years 
old. 
Biliary atresia was the native liver disease in 8 of the 
15 pediatric recipients, with cirrhosis a distant second 
(Table 1). The youngest child was 4.5 months old. The 
average degree of urgency in these patients was less than 
in the adults. 
Liver Retransplantation (20 Cases) 
These 20 patients (15 adult and 5 pediatric) experienced 
failure of one to five previous grafts that had been in place 
for 2 days to 80 months under cocktail immunosuppres-
sion with cyclosporine and prednisone, with or without 
azathioprine and/or antilymphoid globulin (ALG) agents 
(Table 2). The main reasons for graft failure were chronic 
rejection and hepatic artery thrombosis (Table 2). Several 
of these patients were sent to Pittsburgh for salvage after 
having their first transplantation(s) at other centers. 
TABLE 2. Circumstances of Liver Retransplantation (ReTXJ 
Circumstance Adult (;, 18 years) Pediatric ( < 18 years) 
Number of patients 15 5 
Number of transplants 18 5 
Age (years) 45 ± 4.5 (21 to 64) 5.6 ± 6.5 (I to 17) 
Sex (M/F) 7/8 2/3 
Causes of ReTx: 
No. of cases and % ( ) 
Rejection 8 (53.3) 5 (100) 
HA thrombosis 4 (26.7) 
Primary dysfunction 2(13.3) 
Recurrent HBV 
Number ofi~rafts 
1 (6.7) 
2 10 4 
3 4 1 
6 1 
Days from 
First graft 728 ± 862 (2 to 2435) 478 ± 278 (84 to 862) 
Previous graft 460 ± 594 (2 to 2421) 475 ± 251 (84 to 862) 
Biliary atresia 
Cirrhosis 
Tumor 
Fulminant failure 
t Included 9 B-virus (HBV) carriers. 
8 (53.3) 
4 (26.7) 
2 (13.3) 
I (6.7) 
• 
15 (100) 
5 (33.3) 
5 (33.3) 
3 (20.0) 
2 (13.4) 
Treatment of the 20 patients required 23 grafts because 
additional retransplantation became necessary in three 
instances. 
Thoracic Organ Transplantation 
Heart transplantation. Between October 8, 1989 and 
February 14, 1990, heart transplantations were performed 
in eight adults (48 to 56 years) and three children (who 
were 11 months, 2.5 years, and 11 years old). The indi-
cations were idiopathic cardiomyopathy (n = 5), ischemic 
cardiomyopathy (n = 5), and congenital heart disease (n 
= 1). Four of the 11 patients needed preoperative me-
chanical assist device support and three more required 
inotropic drugs. The donor for a 52-year-old woman was 
her 48-year-old sister (one haplotype HLA match) who 
died of a stroke; special permission was obtained from 
UNOS to permit allocation outside of the normal priority 
list. 
Lung or heart-lung transplantation. Two men with 
cystic fibrosis who were 34 and 27 years old had double-
lung transplantation on October 13 and November 28, 
1989, respectively. A 27-year-old woman with Eisenmen-
ger complex had a heart-lung transplantation on October 
20, 1989. She had minimal residual disability from a ce-
rebrovascular accident several years earlier, which pre-
sumably was related to polycythemia. 
Kidney Transplantation 
Thirty-six kidney transplantations were performed be-
tween March 27, 1989 and January 4, 1990 and have 
been reported elsewhere.4 More than two thirds of these 
patients were not conventional kidney transplant recipi-
ents because of previous or concurrent transplantation of 
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the liver (n = 10) or heart (n = 1), positive cytotoxic cross-
matches (n = 9), and other complicating factors that nor-
mally would have precluded renal transplant candidacy. 
Two (5.6%) of the patients died. Twenty-seven (75%) have 
good graft function (mean serum creatinine, 1.7 mg%) 
after 3 to 13 months follow-up (156 ± 52 [SD] days). In 
the present report, these cases were used for comparison 
of FK 506 doses, FK 506 plasma levels, and cholesterol 
concentrations with those of primary liver and thoracic 
organ recipients. 
Immunosuppression 
FK 506. Initial treatment is the same with all organ 
recipients and has been standardized as follows. Intra-
venous doses of 0.075 mg/kg infused during 4 hours are 
started in the operating room and repeated every 12 hours 
until oral intake is begun. The conversion from intrave-
nous to oral doses of 0.15 mg/kg every 12 hours usually 
is overlapped for 1 day. Dose revisions are made on clin-
ical grounds and guided by trough plasma levels of FK 
506, which are measured with an enzyme immunoassay 
technique.6 Optimal 12-hour trough levels are thought to 
be in the 0.5 to 1.5 ng/mL range, but concentrations less 
than this may be adequate, and higher concentrations may 
be well tolerated.4 Most upward dose adjustments are re-
sponses to the break-through of rejection, combined with 
low plasma levels ofFK 506. Downward dose adjustments 
usually are dictated by adverse drug reactions of which 
neurotoxicity is the most common and useful for clinical 
management.4 Major nephrotoxicity implies serious 
overdosage but is quickly reversible. 
Later, variations from this generic approach were dic-
tated by the nature of the graft, the quality of graft func-
tion, and kidney function in nonrenal and renal recipients. 
Because the principal metabolism of FK 506 is by the 
liver, the doses were reduced after hepatic transplantation 
if the initial liver graft function was substandard. Under 
these circumstances, downward adjustments of FK 506 
dosage were correlated with liver dysfunction, declining 
renal function, neurotoxic side effects, and the demon-
stration of supratherapeutic plasma levels of FK 506. 
These were documented as high as 25 ng/mL. The su-
preme value of monitoring plasma levels of FK 506 was 
in the liver recipients. In liver recipients upward adjust-
ments of FK 506 dosage from the generic regimen were 
rarely made perioperatively and then only if there was 
unequivocal evidence of rejection. Protocol liver biopsies 
were obtained at 2 weeks and 2 months to help guide 
management. 
An effort was made in recipients of thoracic organs to 
keep the FK 506 doses as high as possible. Perioperatively 
renal dysfunction necessitated temporary reduction of the 
intravenous doses in one half of the cases. This was most 
common when circulatory or pulmonary assist procedures 
had been in effect before operation. Later, changes in im-
munosuppression were based on the histologic findings 
in serial endomyocardial or lung biopsies and the results 
of bronchopulmonary lavage specimens. The initial re-
sponse to a rejection was to increase the FK 506 dose if 
renal function was adequate. This approach permitted 
the double-lung recipients and the heart-lung recipient 
to be managed without maintenance steroids or any other 
adjuvant agent. 
Kidney recipients were managed in the same general 
way as heart patients. Elevations of creatinine were eval-
uated with standard radiologic studies and kidney biopsies 
were obtained as needed to establish the differential di-
agnosis of rejection versus nephrotoxicity or ischemic in-
jury. I n such cases FK 506 doses were increased if there 
was evidence of rejection with little or no toxicity, or re-
duced if the biopsy did not show rejection. 
Other drugs. All of the patients reported here, except 
for the lung and heart-lung recipients, also were given 
prednisone. In the first part of the experience, I g intra-
venous methylprednisolone was given to adults during 
operation, and a 5-day burst of methylprednisolone was 
begun at 200 mg on the first day and reduced daily in 40-
mg steps. The doses were scaled down for infants and 
children. Beginning in late 1989, the intraoperative bolus 
and subsequent steroid cycle were omitted. Instead a daily 
dose was started of 20 methylprednisolone. Prednisone 
doses were reduced to 0 to 10 mg/day during the second 
to sixth post-transplantation weeks if there was no evi-
dence of rejection. 
Rejection episodes that were unresponsive to increasing 
the maintenance doses of FK 506 were treated with a 
single I-g bolus of methylprednisolone or hydrocortisone 
in adults or with lesser quantities in children. If rejection 
persisted additional steroids were given, a 3- to 5-day 
course of 5 or 10 mg/day OKT3 was considered, and in 
a few cases azathioprine was added. 
Tissue Matching 
As would be expected with random matching, poor 
HLA compatibility was present with all of the extrarenal 
transplantations, except for the sister-to-sister heart trans-
plantation. Efforts at matching in the renal cases were 
completely unsuccessful, despite considerable effort.4 
Twelve (10%) of the 120 primary liver transplantations 
were performed, despite completely killing positive cy-
totoxic cross-matches. All but one of these recipients had 
a panel reactive antibody index (PRA) :;,. 40%. None of 
the thoracic transplant recipients had circulating cytotoxic 
antibodies. 
---- ---- -----------------------------_. 
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Data Analysis 
Patient and graft survival were recorded for each organ 
and actuarial survival was projected with Kaplan-Meier 
analyses. Data compilations were expressed as mean 
± standard deviations (SO). Data from our recently re-
ported FK S06-treated kidney recipients were used for 
comparisons of the FK S06 doses, blood levels, and cho-
lesterol levels with those in recipients of other organs. 
Comparisons were made with a one-tailed student's t test 
and X2 test with continuity correction and were consid-
ered significant at p < O.OS. 
For comparison of the present results with our previous 
liver transplantation experience, 400 consecutive primary 
transplant cases were studied, going back from November 
8, 1988 to October 2S, 1987. Then, as during the FK S06 
study, all livers were preserved with University of Wis-
consin (UW) solution. The historical controls had about 
the same adult and pediatric case representation as during 
the FK S06 study. Historical controls from November 
1988 onward were not useful because so many of the later 
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TABLE 3. Causes of Retransplantation (RTx) Within 60 Days 
After Primary Liver Transplantation Under FK 506 
Versus Historical Controls 
FK 506* Cyclosporine 
N (Starting) 120 400 
p 
N (RTx) 7 (5.8%) 60 (15%) <0.05 
Reasons for R Tx 
Rejection I (0.8%) 15 (3.8%) 
Artery thrombosis 1 (0.8%) 9 (2.2%) 
Primary dysfunction 5 (4.2%) 25 (6.2%) 
Viral hepatitis 0 0 6 (1.5%) 
Other 0 0 5 (1.3%) 
Outcome of second transplantation: Five of the seven FK 506 patients 
are alive 3 to 5.5 months later. One of the patients who died received a 
total of three livers. The 90-day survival rate after retransplantation in 
the cyclosporine group was 34 of 60 patients. 
* The patient and graft survival curves up to and beyond 60 days after 
plimary transplantation are shown in Figure 1. Two more patients re-
quired retransplantation after 60 days in the FK 506 series, and both 
patients survived after receipt of their second graft and in one case a 
subsequent third graft. 
patients eventually were switched from cyclosporine to 
FK S06.2 In addition to patient and graft survival in all 
400 cases, several other biochemical and treatment pa-
rameters were examined in smaller numbers that were 
determined by data availability. 
Results 
Primary Liver Transplantation 
Patient and graft survival. One hundred twelve (93.3%) 
of the 120 patients are alive after 2 to 7.S months. The 
patient (p < 0.0001) and graft (p < 0.0003) survival was 
superior to that in the historical controls (Fig. 1, top). 
This advantage was seen both in the adult (Fig. 1, middle) 
and pediatric cases (Fig. 1, bottom), although the numbers 
did not reach significance in the infants and children. 
Rate of retransplant at ion. The diminished need for re-
transplantation at all times under FK S06 therapy is ev-
ident in Figure 1 and is documented in Table 3 for the 
first 60 days. Seven retransplantations (S.8%) were per-
formed, an incidence that was almost one third of the 
lS% in the historical control group (p < O.OS). All of the 
usual causes of retransplantation shared in the improve-
ment (Table 3). Also noteworthy was the absence of graft 
losses from viral infection. 
The only FK S06-treated graft that was lost to rejection 
was in a highly sensitized patient who had a PRA of 100%, 
and completely killing positive antidonor cytotoxic cross-
matches. This liver was not hyperacutely rejected (Fig. 
2), but intense lymphocytic infiltration was found on 
biopsies 7 and 29 days after operation (Fig. 2). A second 
liver was transplanted after 40 days, also against positive 
cross-matches. This graft eventually provided normal 
function under intensified immunosuppression (Fig. 2) 
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operation and has had prednisone reduced to 5 mg/day. Note the creatinine rise, which occurred as FK 506 was increased to supernormal levels. 
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but at the cost of nephrotoxicity from high-dose FK 506 
therapy. 
It may be significant that three of the retransplantations 
within 60 days in the FK 506 series were in patients with 
strongly positive cytotoxic cross-matches. These early graft 
losses were from the total of 12 cases in which livers were 
confronted with such cross-matches. The 60-day graft loss 
of 25% in the cross-match-positive cases versus 3.7% (4 
of 108) in the cross-match-negative cases was significant 
(p < 0.05). 
Causes o/death. Eight (6.7%) of the 120 primary liver 
recipients died within 60 days for the reasons summarized 
in Table 4. There have been no deaths after 60 days. The 
60-day mortality rate was significantly less than in the 
historical controls (p < 0.05). Two of the deaths were 
after emergency retransplantation. Sepsis caused 4 of the 
8 deaths. However lethal sepsis occurred at a much re-
duced rate compared to the historical controls (p < 0.05). 
The fatal intraoperative complication (Table 4) was 
caused by an unrecognized laceration of the subclavian 
artery in a 4-year-old child during anesthesia induction 
and placement of a central line. The patient was given 
only a partial first dose of FK 506 before developing an 
TABLE 4. Causes (j{60-day Mortality* After Primary Liver 
Transplantation (FK 506 Versus Historical Controls) 
FK 506 Cyclosporine p 
N (starting) 120 400 
N (deaths) 8 (6.7%) 66 (/6.5%) <0.05 
Causes of death 
Sepsis 4 (3.3%) 40 (10%) <0.05 
Intraoperative 1 (0.8%) 7(1.8%) 
Liver failure 0(0%) 6 (1.5%) 
Heart failure 1 (0.8%) 4 (1%) 
Stroke I (0.8%) 1 (0.2%) 
Others 1 t (0.8%) 8 (2%) 
* There have been no deaths after 60 days in the FK 506 group. The 
continuing mortality in the historical controls is evident in Figure I. 
t Fulminant failure: failed to wake up. 
-------------D~--~~ .. -~---K-----
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acute hemothorax. Another child with fulminant hepatic 
failure did not wake up after the transplantation. Because 
of our policy of agressive retransplantation, the incidence 
of death from hepatic failure was low in both the FK 506 
and historical cases. 
Liver function. One hundred twelve of the starting 120 
primary liver recipients are alive, 7 after retransplantation 
(5 before 60 days and 2 after 60 days; Table 3). The func-
tion of the 105 grafts that have been in place continuously 
for 2 to 8.5 months is shown in Table 5. Only one patient 
with a recent biliary reconstruction has a bilirubin level 
more than 2 mg%. The serum glutamic oxaloacetic trans-
aminase and alkaline phosphatase values are also normal 
or only slightly elevated in almost all cases. 
The seven other patients who are alive after retrans-
plantation also have generally good liver function, with 
only one exception. 
Steroids, rejection, and adjuvant immunosuppression. 
Most FK 506 patients can be weaned from the prednisone 
rapidly during the first month (Figs. 3 and 4), leaving the 
FK 506 survivors on an average prednisone dose of only 
6.6 mg/day at the end of this time compared to 16.7 mg 
in the historical controls (p < 0.05). Further steroid re-
ductions were routinely made so that by 2 and 3 months 
the daily average doses were much less than 5 mg, signif-
icantly less than in the historical controls (Fig. 5). The 
appreciation of the inter-relationship between rejection 
and all modalities of immunosuppression during the first 
30 days can be gained from Table 6. The absolute rate of 
clinical rejection was less (p < 0.01) in the FK 506-treated 
patients than in the historical controls, but only slightly 
less (NS) by histopathologic criteria. At the same time, 
the FK 506 patients were given only 43% of the steroid 
TABLE 5. Present Metabolic Status of 105 Liver Recipients (87.5% of 
Original 120) Whose Primary Transplantations Were August 17, 1989 
to Fehruary 4. 1990. Datafrom Seven Other Surviving Primary 
Recipients who Required Retransplantation Are 
No/Included (Mean ± SD). 
N 
105 Days survival 
*105 Bilirubin (mg%) 
105 SGOT (lUlL) 
t92 Alkaline phosphatase (lUlL) 
t92 Serum cholesterol (mg%) 
95 Uric acid (mg%) 
105 BUN (mg%) 
105 Creatinine (mg%) 
61 Magnesium (mg%) 
128 ± 46 
0.8 ± 1.3 
50.3±57.1 
153 ± 136 
160 ± 53 
6.9 ± 4.2 
24.5 ± 12.3 
1.4±0.7 
1.3 ± 0.3 
Normal values of: cholesterol: 130 to 240 mg% (age dependent); uric 
acid: <8.5 mg% males, <7 mg% females; magnesium: 1.8 to 2.4 mg%. 
* Only one patient with recently repaired duct obstruction has a bil-
irubin ~ 2 mg%. 
t Adults only. 
SGOT. serum glutamic oxaloacetic transaminase. 
BUN, blood urea nitrogen. 
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CY A, cyclosporine. 
The simplified management made possible by FK 506 
in most patients is seen in Figures 3 and 4. Rapid recovery, 
early discharge from the hospital, and steroid discontin-
uance were possible in more than one third of the cases 
(Fig. 3). The patient whose course is summarized in Figure 
4 had a significant rejection that was easily reversed with 
a single steroid bolus and an increase of the FK 506 dose. 
Other metabolic tests in FK 506 patients. Present av-
erage renal function in the 105 liver recipients still bearing 
their original hepatic grafts is nearly normal (Table 5), as 
judged by serum creatinine and blood urea nitrogen. Cur-
rent serum cholesterol, serum uric acid, and serum mag-
nesium in the same patients are summarized in Table 5. 
In(ectiolls complications. The reduced incidence offatal 
infections was documented in Table 4. However the pat-
terns of nonlethal infectious disease were similar to other 
immunosuppressive regimens and included wound infec-
tions requiring treatment with antibiotics or surgical 
drainage, urinary tract infections, pneumonias, and fungal 
infections. The most common virus infection was cyto-
megalovirus. There were no protozoan infections. 
Lymphoma. Polyclonal lymphoproliferative disease 
developed in two patients who had Epstein-Barr virus 
infections. A 19-year-old man had an infectious mono-
nucleosis syndrome with enlargement of tonsils. After 
tracheostomy, tonsillectomy, reduction of the FK 506 
dose, and treatment with acyclovir, he recovered and has 
no residual effects 5 months later. A 65-year-old woman 
with a PRA of 100% and a positive cytotoxic cross-match 
rejected both her primary and a second liver, despite ad-
ditional therapy with high doses of prednisone, multiple 
courses of OKT3, and azathioprine. She died of sepsis 9 
days after a third transplantation. The second graft con-
tained a polyclonallymphoma with no other foci. 
Adverse reactions. Two of the 120 primary liver recip-
ients developed transient expressive aphasia 6 and 11 days 
after transplantation. These cases have been reported in 
detail.? Other major neurologic complications, such as 
convulsions and coma, were not seen. One patient who 
died of cerebral hemorrhage 4 days after operation had 
thrombocytopenia (platelet count lO,OOO). Minor neu-
rotoxic symptoms such as tremors, paresthesias, increased 
sensitivity to light, insomnia, and mood changes were 
common and were helpful in guiding dose adjustments.4 
Ten of the one-hundred twenty primary liver recipients 
developed new-onset diabetes requiring insulin. If only 
the 112 survivors are considered, the incidence was 8.9%. 
The incidence of new diabetes in kidney recipients treated 
with cyclosporine regimens has been reported to be lO0'o 
to 20%.8.9 
There were no examples of hirsutism, gingival hyper-
plasia, or gynecomastia. A few patients noted thinning of 
the hair. 
Liver Retransplantation 
These 20 patients (15 adults and 5 children) had been 
under treatment that included cyclosporine and predni-
sone. Seventeen (85%) are alive with follow-ups of 2.3 to 
9 months (Fig. 6). Two of the three patients who eventually 
TABLE 6. Other Immunosuppressive Agents and Rejection 
in Patients Within 30 Days Ajier Liver Transplantation 
FK CyA p< 
N 120 303 
Steroid bolus No 77 (64.2) 51([8.8) 
Yes 43 (35.8) 252 (81.2) 0.001 
Steroid recycle No 117 (97.5) 201 (66.3) 
Yes 3 (2.5) 102 (33.7) 0.001 
Irnmuran No 117 (97.5) 113(37.3) 
Yes 3 (2.5) 190 (62.7) 0.001 
OKT3 No 107 (89.2) 159 (52.5) 
Yes 13 (10.8) 144 (47.5) 0.001 
Rejection 
Clinical No 73 (60.8) 138 (45.5) 
Yes 47 (39.2) 165 (54.5) 0.01 
Histopathologic" No 51/106 (48.1) 104/248 (41.9) 
Yes 55/106 (51.9) 144/248 (58.1) NS 
.. The pathology data were not obtained under comparable circum-
stances. All of the adult FK 506 patient~ had protocol biopsies at 2 weeks 
and 2 months, whereas the livers in the historical control cases were 
sampled irregularly. A valid comparison of histopathology will require 
a randomized trial and protocol biopsies in both limbs. 
NS, not significant. 
._---------- .-----.. ---
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23 GRAFTS USED 
3 DEATHS BY SEPSIS 
FOLLOWUP : 2 TO 9 MONTHS 
FIG. 6. Survival of patients whose previous grafts were lost under cyclo-
sporine regimens and who underwent retransplantation with FK 506 
treatment. 
died of sepsis had a further attempt at retransplantation, 
in one patient twice, accounting for a total use of23 grafts 
to treat these 20 recipients. The third death was in a child 
with perfect graft function who had a respiratory arrest 
on the ward, probably because the transplanted liver was 
too large for the body size. 
The 17 patients who survived had more infections, a 
higher incidence of renal failure, and longer hospitaliza-
tions than did the patients in the primary series. However 
liver graft function at 30 days and subsequently was 
equivalent to that in the primary transplantation series. 
One of the survivors was a child who underwent pancre-
aticoduodenectomy because of pre-existing pancreatitis 
that became· hemorrhagic after operation. Pre-existing 
hirsutism and gingival hyperplasia in patients who had 
been on chronic cyclosporine therapy reversed in 1 to 2 
months. 
Transplantation of Thoracic Organs 
A detailed report of these cases is scheduled for pre-
sentation to the American Society of Transplant Surgeons 
in June 1990 and the International Transplantation So-
ciety in August 1990. The two double-lung and the heart-
lung recipients are well after 130, 165, and 173 days, re-
spectively, never having received maintenance steroid 
therapy. One of the double-lung recipients has been sus-
pected to have bronchiolitis obliterans because of biopsy 
findings. Because he has no complaints or deterioration 
of pulmonary function, other maintenance immuno-
suppression has not been added to FK 506. 
The 11 heart recipients also are well after a mean sur-
vival time of 104 ± 54 (SO) days (51 to 180 days). One 
adult was treated with OKT3 and started on azathioprine 
as a third maintenance drug after 3 months because of 
histopathologic evidence of rejection. An ll-year-old child 
was switched by his pediatric cardiologist from FK 506 
to azathioprine after 3 months, probably with insufficient 
reason. Other potentially important information is sum-
marized in Table 7. The patients have been unusually 
free of the hypertension that was common in the historical 
controls. Serum creatinine concentrations were approx-
imately the same in both groups. The serum cholesterol 
levels are less than in the historical controls but not sig-
nificantly so. 
Kidney Transplantation 
Current data on the 27 kidney recipients with func-
tioning grafts are summarized in Table 8. The low steroid 
TABLE 7. Parameters in Surviving Heart Transplantation Recipients 
Parameter FK 506 Cyclosporine 
Days 0 30 51-90 0 30 51-90 
n II 11 11 40 36 35 
Prednisone (mg/day) 13.6 ± 7.2 10.7 ± 8.5 17.8 ± 4.7 18.0 ± 4.5 
Antihypertensive drugs 
One 0/1 [ 1/[ [ 11/36 19/35 
Two 0/11 0/[ I 2/36 1/35 
Tota[ 0/[ I 1/11 (9%) 13/36 (36%) 20/35 (57%) 
Serum cholesterol 
(mg%) 210 ± 52 220 ± 52 216 ± 41 245 ± 55 
Serum creatinine 
(mg%) 1.1 ± 0.6 1.4 ± 0.8 1.0 ± 0.4 1.2 ± 0.5 
Vol. 212· No.3 LIVER, KIDNEY, AND THORACIC ORGAN TRANSPLANTS UNDER' FK 506 303 
TABLE 8. Present Metabolic Status of 27 Kidney Recipients Whose 300 
Primary Transplantations Were March 27, 1989 to January 4, 1990· 
Mean number of days after transplant 
Creatinine (mg%) 
Blood urea nitrogen (mg%) 
Uric acid (mg%) 
Magnesium (mg%) 
Serum cholesterol (mg%) 
Patients on antihypertensives 
Daily prednisone (mg)t 
Renal 
Recipients 
156 ± 52 
1.75 ± 0.75 
29.3 ± 13.8 
7.0 ± 2.3 
1.5 ± 0.3 
176 ± 44 
11/28 
4.3 ± 6.2 
Normal 
Values 
0.5-1.4 
5-20 
2.5 ± 8.5 
1.3 ± 2.1 
160-250 
• Details of all patients in this complex series are reported elsewhere.4 
t Twenty of the 28 patients are receiving no steroids; four are on 5 
mg/day. 
doses, good average renal function, relative freedom from 
hypertension, and low serum cholesterol levels are good 
prognostic signs that have prompted the institution of a 
randomized trial in more conventional renal candidates. 
Figure 7 shows a comparison of the serum cholesterol 
in these renal recipients with those in the liver and heart 
recipients. The lowest values were in the liver recipients, 
and the highest were in the heart recipients. The two dou-
ble-lung and heart-lung recipients had very low choles-
terol levels. 
A similar interorgan comparison is shown in Figure 8 
for FK 506 doses and plasma blood levels. Kidney recip-
ients appeared to require higher doses to maintain plasma 
levels equivalent to those of the liver patients. The thoracic 
organ recipients were more heavily treated as a policy and 
had higher plasma levels. 
Discussion 
The accomplishments in transplantation during the last 
30 years, and exponentially in the last decade, have ex-
ceeded expectations. Small steps, widely spaced in time, 
became large leaps with the advent of cyclosporine. Yet 
the nephrotoxicity and other side effects of this drug lim-
ited its value and stimulated a search for better agents. 
FK 506 was a product of this search. It was discovered in 
Japan by Kino et al. tO in 1984 during systematic screening 
for drugs with antimicrobial, antineoplastic, or immu-
nosuppressive qualities. 
FK 506 is a macrolide antibiotic (such as erythromcyin) 
that is recovered from the fermentation broth of the soil 
fungus Streptomyces tsukubaensis. FK 506 has no struc-
tural similarity to cyclosporine, but it has in common the 
ability to inhibit the synthesis and expression of interleu-
·kin-2 and other cytokines, including gamma inter-
feron. IO- 12 Like cyclosporine, FK 506 suppresses T-Iym-
phocyte activation, adoptive immunity, and alloreactivity 
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FIG. 7. Serum cholesterol comparison in recipients of different organ 
recipients. 
(rejection) in vitro and in homotransplantation models. 
The drug can mitigate or prevent the rejection of heart, 
liver, kidney, pancreas, lung, intestine, 'and skin grafts in 
mice, rats, dogs, monkeys, baboons, and humans. The 
. international exchange of this burgeoning information was 
facilitated by satellite symposia of the European Society 
of Organ Transplantation in 1987 and 1989.13,14 Clinical 
trials have been in progress in Pittsburgh since February 
1989. The ultimate role of FK 506 in transplantation 
practice has not been fully delineated, but there are in-
dications from our experience that it may be a large one. 
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FK 506 was used first clinically to treat liver recipients 
whose convalescence was unsatisfactory under cyclo-
sporine-containing regimens. 1,2 However all of the trans-
plantations in the present report were with FK 506 therapy 
from the outset.3 Because of the variety of the organ grafts, 
specific questions could be addressed about toxicity, dose 
requirements, and metabolic changes that might have 
been less accessible with only one kind of organ graft. 
With both primary hepatic transplantation and re-
transplantation, there were high rates of graft and recipient 
survival. The patients treated were thought to be of the 
same level of difficulty if not greater than in our past ex-
perience. Extremely ill, old, or very young patients were 
represented in large numbers as well as those with hepatitis 
B virus infections, renal failure, previous portal-systemic 
shunts, and multiple upper-abdominal operations. 
The improvement in results with FK 506 compared to 
historical liver transplantation controls began with a 
greatly reduced need for retransplantation. A distressing 
statistic in most liver transplantation centers has been a 
10% to 20% incidence of primary graft nonfunction (usu-
ally dysfunction), which has been explained by undetected 
pre-existing donor disease, poorly performed procure-
ment, inadequate preservation, or a flawed recipient op-
eration. ls Despite the validity of these various explanations 
in some cases, there has been a surprising lack of corre-
lation between recipient outcome; the use of so-called 
good, mediocre, and poor donors; or the surgeon's per-
ception of his or her technical performance. IS The low 
incidence of primary graft dysfunction and a reduced rate 
of hepatic artery thrombosis in the FK 506 patients may 
be indirect evidence that many early postoperative graft 
dysfunctions or thrombotic events are caused by immu-
nologic factors that have not been recognized. In a few 
cases, there has been strong evidence that this can occur, 
despite a negative cytotoxic cross-match. 16 In the present 
report, the cytotoxic cross-match was identified as a special 
but surmountable problem. 
In addition to high survival rates after both primary 
liver grafting and retransplantation, the quality of liver 
function was generally good, reflecting excellent control 
of rejection. This was achieved with low steroid doses and 
with minimum need for the azathioprine or the ALG 
preparations that have been used in cyclosporine 'cocktail' 
regimens. There was a low incidence of nephrotoxicity in 
the primary recipients not previously exposed to cyclo-
sporine and a somewhat greater incidence in the retrans-
plantation series. The arterial hypertension that has been 
associated with cyclosporine therapyl7 was very uncom-
mon. Hirsutism and gingival hyperplasia were never seen 
in fresh cases and disappeared in retransplant recipients 
when they were switched from cyclosporine to FK 506. 
The impression should not be left that FK 506 is free 
of nephrotoxicity. Nephrotoxicity is merely less than that 
of cyclosporine, and seemingly more reversible. Neph-
rotoxicity was uncommon in the liver recipients and was 
not used as a barometer to establish a dose ceiling. How-
ever, in our double-lung and heart-lung recipients in 
whom steroids and other immunosuppressive adjuncts 
were avoided, FK 506 was given to the limit imposed by 
elevations in the serum creatinine to more than 2 mg%. 
These results have given a very favorable impression 
ofFK 506. Whether comparisons with historical controls 
are valid or fair remains to be determined in future ran-
domized trials because excessive immunosuppression, 
particularly with prednisone, may have been given in the 
recent control cases. Ten years ago, when cyclosporine 
was first used with steroids for liver transplantation, pred-
nisone was used sparingly and discontinued early when 
possible. The results were comparable to those obtained 
at other centers in later years. 18 By the late 1980s, a world-
wide drift had occurred (including at our center) toward 
complicated multiple-drug management for all kinds of 
organ transplantation in an effort to minimize cyclo-
sporine nephrotoxicity. Kahan 17 has pointed out that there 
have never been well-designed randomized trials to test 
the legitimacy of this now widely accepted practice. In-
stead of reflecting better immunosuppression when cy-
closporine was used with multiple other drugs, much of 
the improvement in global results after liver transplan-
tation could be due instead to better preservation methods, 
acquisition of surgeon experience, improvements in in-
fectious disease management, and more discriminating 
case selection by teams striving to establish credibility. 
This last factor may be the most important of all in a 
competitive market place in which survival claims can 
make or break a program. How profoundly the seriousness 
of pre-existing disease and other risk factors, including 
age, can influence the outcome has been demonstrated 
precisely in patients with primary biliary cirrhosis. 19 
Whatever the merit of these reservations, the advantage 
of a simple FK 506-steroid management regimen ap-
peared to be the same with other organs than the liver. 
For example, in the heart recipients, of whom all II are 
alive, neither permanent renal dysfunction nor serious 
hypertension have been observed during follow-ups of 2 
to 6 months. Because cholesterol is thought to be up-
regulated by cyclosporine,20 particular attention was paid 
to serum cholesterol levels in the FK 506-treated patients. 
Using FK 506, cholesterol levels have been reported to 
be low to normal in kidney recipients,4 and these were 
even lower in the liver, the lung, or heart-lung recipients 
in the present report (Fig. 7). However cholesterol lowering 
was not evident in the 11 heart recipients of the present 
report, possibly because they were being given more ste-
roids than the other organ recipients. Alternatively hy-
percholesterolemic patients may have been over repre-
sented in the heart group of whom five of the II had 
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coronary artery disease. If the cholesterol-lowering qual-
ities of FK 506 can be validated with more experience, 
cyclosporine-related hypertension and hyperlipidemia, 
two of the most serious present-day risk factors for cor-
onary artery disease in heart, kidney, or liver recipients 
may be ameliorated. 
FK 506 has additional metabolic effects. In addition to 
its immunologic and other qualities, which have been dis-
cussed, it is diabetogenic to the same extent as cyclo-
sporine, augments hepatic regeneration, and can be neu-
rotoxic. It has become increasingly apparent that many, 
ifnot all, of the organ systems and physiologic end points 
affected by FK 506 are the same as for cyclosporine, al-
though to differing degrees and sometimes in opposite 
directions.4.21 This was puzzling at first because FK 506 
and cyclosporine have no structural similarities and have 
different cytosolic binding sites. However now it is sus-
pected that the two drugs may act on an enzyme called 
cis-trans peptidyl-prolyl isomerase (PPIase), which is a 
principal constituent of the binding sites.22.23 PPIase, 
which was discovered in the pig kidney in 1984,24 is widely 
distributed in tissues from the lowest to the most devel-
oped species, including humans. Although PPIase was 
known to facilitate the biologically important process of 
catalysis of oligopeptide bonds and to facilitate protein 
folding,24 the physiologic significance of PPlase did not 
begin to come to light until its possible role in immune 
modulation was realized.22.23 We have speculated that the 
positive as well as adverse immunologic and other wide-
ranging effects of FK 506 and cyclosporine result from 
alteration (probably inhibition) of the PPIase system in 
many tissues in ways that are not yet understood.21 
The influence of the route of administration on these 
diverse effects also is being clarified by observation of pa-
tients. Because orally administered FK 506 and cyclo-
sporine are presented in high concentration to the liver, 
and largely metabolized there, it has been suggested that 
they might be more effective in protecting liver grafts from 
rejection than in protecting other organs, such as the heart 
and kidney, which are beyond this first pass 'filter.'25 No 
conclusions are possible about this possibility. The liver 
recipients have been maintained on smaller average doses 
of FK 506 and with lower plasma levels than recipients 
of kidneys or thoracic organs. The average doses have 
drifted down in liver recipients largely in response to mi-
nor complaints of toxicity and because higher doses did 
not seem necessary for control of hepatic rejection. This 
may have reflected physician policy rather than any fun-
damental biologic difference. Alternatively the difference 
in FK 506 dosaging with the liver versus the nonhepatic 
transplantations might be because of subtle dysfunction 
of transplanted livers, which would not be a comparable 
factor of FK 506 drug disposition in heart or kidney re-
cipients who usually have normal native livers. 
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DISCUSSION 
DR. FELIX T. RAPAPORT (Long Island, New York): I want to con-
gratulate Tom Starzl for his outstanding presentation as well as for re-
ceiving the Association's highest award for scientific achievement. When 
the early studies of FK 506 were first presented in 1987, it was quite 
clear that Tom and his group were the only ones who believed that this 
agent was any good or had any potential whatsoever. We see today the 
fruition of Tom Starzl's efforts, exhibiting that tenacious faith and 
boundless energy of his in developing what is clearly a new milestone in 
immunosuppression. 
It is an irony of nature that the one species .that seems to be least 
susceptible to the toxic effects of FK 506 is its ultimate beneficiary, the 
human subject. 
The importance ofFK actually may reach far beyond transplantation, 
as Tom Starzl just noted, using autoimmune disease as one example. 
It is quite possible that FK may be a model probe for further study 
of the molecular aspects of immune responsiveness and cell function. 
Along these lines, while FK seems to exert the same immunosup-
pressive effects as cyciosporine, I was struck, in seeing the manuscript, 
that Tom was kind enough to show one that there were key differences 
between these two agents. They have different binding sites on the lym-
phocyte surface; FK is a hair thinner, using cyclosporine causes hirsutism: 
FK has no effect on the blood pressure, and may actually even decrease 
serum cholesterol levels, while cyclosporine produces hypertension and 
hyperlipidemia. Finally, FK seems to facilitate transplantation in the 
face of positive cross matches for anti-HLA antibodies, albeit with a 25% 
failure risk. 
One wonders whether this agent, therefore, could not also be of rel-
evance to facilitate ABO-incompatible transplantation, as a potential 
model for xenotransplantation. 
The results that Dr. Starzl lists in his manuscript suggest that it may 
be possible that even the most violent humoral-mediated rejection might 
require the participation of cell populations that can be rendered incom-
petent by an agent such as FK. 
I would be very interested to hear Dr. Starzl's comments on this pos-
sibility. 
Dr. Starzl also suggests in his manuscript that FK might exert its effect 
by inhibiting an enzyme. PPIAse, which is a component of the receptor 
sites for both cyclosporinc and FK. I would like to ask Dr. Starzl whether 
this enzyme is also a component of other major immunomodulating 
receptors on the lymphocyte surface, such as CD4, CD8, or DR, for 
example, and whether the expression of such other markers is affected 
in any way by FK. 
My final question relates to the more profound immunosuppressive 
efficacy of FK. Could this be the 'missing link' in our life-long goal of 
inducing specific tolerance to allografts in humans? 
DR. G. KUNTMALM (Dallas, Texas): I want to express my profound 
admiration for Dr. Starzl, not just for the work that he has presented, 
but also for bringing this drug from the laboratory to the clinical setting. 
This is truly a hallmark presentation, and I think we see here the first 
drug in the next generation of immunosuppressive drugs. 
As indicated in the abstract, we do not sec as impressive a result after 
kidney transplantation as with heart-lung or liver transplantation. The 
same has actually been reported by Dr. Starzl's group in the canine 
model. Do you believe there may be a first-pass effect of FK that may 
be responsible for this difference? 
DR. OSCAR SAL V A TIERRA, JR. (San Francisco, California): There is 
no group in the United States clinically using FK currently other than 
the Pittsburgh group, and they are to be commended for their courage 
and leadership role with this new agent. 
Previous reports by the Pittsburgh group describe FK in rescue of 
failing grafts under cyclosporine therapy. This report now describes the 
first use of FK as the primary immunosuppressive agent in liver, kidney, 
heart, heart-lung and double lung transplantation from the time of graft 
implantation. 
The report compares the use of FK with a good historical control 
group of patients treated with cyclosporine. the drug that heralded the 
new era of improved transplant success in the 19805. 
It appears from this report, and if the findings are confirmed in future 
clinical trials that will soon begin at other centers, that organ transplan-
tation may now be entering another era of success with hopefully con-
comitant reduced sequelae from multiple drug therapy protocols that 
are currently in use. 
Of great interest is the early significantly improved graft and patient 
survival rates in liver, heart, and/or lung transplantation and decreased 
retransplantation rates in these groups. 
The kidney group is more difficult to evaluate, in that 10 of the 36 
patients had other nonrenal organ transplants and nine had positive 
cytotoxic cross-matches against the donor, conditions that would have 
generally precluded renal transplantation at many centers. Yet 75% graft 
survival was achieved in this complex group. 
The lower incidence of rejection episodes in the FK group of patients 
is extremely important, as it portrays a lesser need for increased or pro-
longed steroid and other drug usage. In fact, rejection was in general 
easily and successfully treated with just one pulse steroid bolus in most 
patients. More importantly, most patients were off steroids or on very 
low steroid dosages. Off steroids were 100% of the heart-lung and lung 
recipients, greater than one third of the liver recipients, and 71% of the 
kidney recipients. 
If one examines these early findings as presented, the 1990s may well 
witness a new and meaningful breakthrough in immunosuppressive 
management. 
I have two questions for Dr. Starzl. Have you established immunologic 
and outcome criteria by which you can safely convert patients to FK 
monotherapy, eliminating steroids? 
Second, kidney recipients appear to require higher doses of FK to 
maintain equivalent plasma levels, as the liver recipients presumably 
related to the initial pass of the drug through the liver and its metabolism 
by that organ. How critical and important is the careful drug dosing by 
plasma levels in the kidney recipient, and how reliable is the currently 
used assay methodology? 
DR. JOEL D. COOPER (St. Louis, Missourj): As has been pointed out 
many times, cyclosporine really ushered in an explosion of transplant 
activity, but we have all been hoping for something better. Perhaps FK 
is that next giant leap forward. 
Primarily I wanted to thank him and acknowledge his assistance with 
one of our patients, a woman who had a double-lung transplant and did 
very well for 15 months, but who then went into fulminant and unre-
lenting rejection. With his encouragement and advice and his offer to 
help us with FK 506 on a compassionate basis, we replaced both her 
lungs. She is now out of the hospital and has done very well. 
I realize that one mouse is no mouse, but certainly in this case the 
use of FK 506 greatly simplified the management of this patient. Dr. 
Starzl lowe you a piece of chocolate cake because she is a wonderful 
cook and brought me a chocolate cake the other day. I think I was 
supposed to bring you a piece, but I ate it. 
DR. JOSEPH E. MURRAY (Wellesley Hills, Massachusetts): It is chal-
lenging to learn of new drugs that are improving the results of human 
organ transplantation. It was in 1962 at a meeting of this Association 
that we first described the effectiveness of immunosuppressive drugs for 
renal transplantation in dogs and man (Ann Surg 1962; 156:337). 
The drugs used then were azathioprine and actinomycin C. The use 
of steroids as a supplement soon followed. Cydosporine came onto the 
scene about 15 years ago, and now we have FK 506. 
I've always been interested in the mechanism of action of these various 
drugs, so I'd like Dr. Starzl's opinion as to whether or not all drugs act 
differently or is there a final common pathway of action. Tom has had 
wide experience going back to the early days of Imuran treatment. 
In our canine renal transplants in the mid 1960s we were pleased and 
surprised to be able to wean completely some of the long-term aUografted 
dogs from the drugs. The same happened in an occasional patient in 
whom we were forced to withdraw therapy for medical reasons. Do you 
feel that FK506 may be able to produce a permacnt tolerance? Is it easier 
to withdraw therapy using FK506 than with other drugs? 
DR. ROBERT E. CONDON (Milwaukee, Wisconsin): I would like to ask 
a few questions that don't have to do with the use of this drug as an 
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immunosuppressant but relate to its status as a macrolide antibiotic. The 
first has to do with possible effects on gut motility. The macrolides stim-
ulate gut smooth muscle in various ways. That is what accounts for the 
nausea that is occasionally associated with the administration of eryth-
romycin, for example. 
So my question is: In your patients, have you noted any change in 
bowel habits, and if so, is the change in transit time responsible for the 
changes that you have noted in the cholesterol levels in your patients? 
The second question has to do with possible antibacterial effects of 
this macrolide. There was a startling improvement in the overall sepsis 
rate in these patients and, although most of that is probably due to the 
fact that they got less steroids, could it possibly be related to some direct 
antibacterial effect of the macrolide drug? 
PROFESSOR PETER J. MORRIS (Oxford, England): I would like to ask 
Dr. StaTZI to comment on the histology. I was very excited about 6 months 
ago when I saw some histology from routine biopsies in patients with 
liver transplants at about 2 to 3 weeks after the transplant, showing no 
evidence of rejection whatsoever. This was a fairly unique finding in the 
relatively small number of transplants done at that time. 
I gather that cardiac transplants on routine biopsy do show a cellular 
infiltrate that looks not dissimilar from what is seen with cyclosporine. 
Again that was, of course, in the first half-dozen patients or so, and I 
would like a follow-up on that. Also, I would be interested to know if 
there is any information on the histology of the kidney transplants. Cer-
tainly the histologic findings in the liver transplants were absolutely dra-
matic and I just wonder if that is unique to the livers. 
DR. THOMAS E. STARZL (Closing discussion): I particularly wanted 
to say hello and thank you to Dr. Murray, to tell him how pleased I am 
to have him hear this paper and to acknowledge the fact that the first 
steps toward the summit, which he took, were the most important ones. 
The question of tolerance induction that Felix Rapaport already discussed 
is a very difficult one. I think as you (Dr. Murray) yourself showed and 
we have emphasized over the years, the accidental achievement of tol-
erance, if that is what it is, probably follows the same pathway using all 
drugs, and so what you saw with those early Boston dogs named Con-
necticut and Massachusetts is probably what we can see today, and induce 
with FK 506 but apparently with greater predictability than at any time 
in the past. It is very difficult to get papers published that actually examine 
the mechanism of graft acceptance, because all such papers interdict the 
opinions or biases of most of the referees. We have such a manuscript 
out there at the moment, which suggests that all hypotheses up to the 
present are wrong. The truth is that we do not know why some grafts 
are accepted, and others are not. 
Of all of the discussions of this morning, I was actually most intrigued 
and learned the most from that of Dr. Condon because he is an expert 
on infectious disease. If Dick Simmons is here, I hope that he heard Dr. 
Condon's two questions, the first being about the potential antibiotic 
effect of the FK. This is a fascinating suggestion, and I wish I had thought 
of it myself. We will follow up your idea, and if you are right, we will 
claim it as our own. 
Concerning the second question, I think that there potentially is an 
effect on GI motility and GI function, although it is very hard to detect. 
In dogs, the GI toxicity of FK 506 was actually what scared off the 
Cambridge group because it made the dogs so sick that many of the 
animals developed intussusception. This was the toxicity that we had 
feared the most in our first humans, but it did not materialize. 
Dr. Klintmalm, I suspect that there is a first-pass removal of FK 506 
by the liver and this may make it easier to treat liver recipients who take 
the drug by mouth and who therefore have it presented in high concen-
tration to the liver. Because a diminished amount leaks through, this 
may make it necessary for larger doses to be given for organs not exposed 
to the splanchnic venous return. If this is a genuine dose-adjustment 
phenomenon, it must also apply, although it has never been studied 
formally, with cyc\osporine. Many of the kinetics including liver metab-
olism of cyc\osporine and FK 506 are similar. So far, the bottom line is 
that the liver recipients do require a smaller dose, as discussed in the 
manuscript. 
Dr. Salvatierra also has asked important questions, of which the fore-
most is which patients can have the steroids stopped. I wish we had a 
foolproof formula for prediction. What we do in practice is go down to 
zero steroids automatically, and then if we get stung with a rejection, we 
resume steroids. The implications of a rejection under those circumstances 
are less grave than in the past, since the patients usually can be rescued 
rather easily from such rejections, Thus, the game is worth the candle 
to try steroid discontinuance at least once with the liver recipients. 
To answer Peter Morris' question about the liver biopsies, there is 
evidence of rejection in many of the biopsies. In kidney grafts, the same 
is true, Drs. Jake Demetris and Barbara Banner, our pathologists, did a 
blind study of cyclosporine versus FK 506-treated kidneys. There was a 
conviction at one time that the vascular lesions of rejection would be 
more common in the FK patients. This was not the case, and in fact the 
findings were the other way around. The vascular lesions occurred at 
about one-third the rate in the FK 506 kidneys compared with the con-
ventional cyclosporine regimen. It is difficult with blind reading to make 
a qualitative distinction about rejection patterns in any given case. In 
both kidney and liver grafts, eosinophils may be prominent with either 
drug. I think that this occurs when there is an effort to move downward 
in steroid doses. 
The heart biopsies are very difficult to interpret. These biopsies tend 
to guide therapy, since there is not a biochemical litmus paper as we 
have with the other organs. The dependence on cardiac graft biopsies is 
very nearly complete, but whether or not those cells that are being found 
in the endomyocardial biopsies should actually trigger responses in ther-
apy is an open question. What we are doing in many of our patients 
whose grafts do have these cells, is to make minimal and sometimes no 
therapeutic adjustment if the patients are well clinically. 
Felix Rapaport and some one else also asked, what can be done with 
FK 506? Can it playa role in research in heterotransplantation? That, 
of course, is the next step, and I think the answer is yes, but. The 'but' 
is that something has to be done about the heterospecific preformed 
antibodies that are present with cross-species grafting. Twenty-seven years 
ago, we showed how close to possible it was even then to transplant 
baboon kidneys to humans. I believe that the cell-mediated rejections 
that occurred with those baboon-to-human transplantations could be 
controlled with the drugs we have today, but what we can not control 
are the humoral rejections. So, Felix, I think that this is the component 
of the problem that we must work on. We are advising against such 
trials, at least at the moment. 
I see that the warning light is blinking that precludes my answering 
the most important question of all about the peptidyl-prolyl isomerase 
(PPlase) enzyme system. This enzyme is contained in the binding sites 
of both cyclosporine (cyc\ophilin) and FK 506 (binding site not yet 
named). These are distinct binding sites, and yet they have as their prin-
cipal constituent the PPIase, which was discovered 5 years ago. PPlase 
had no known function until about a year ago, when it was recognized 
to be the principal constituent of cyclophilin. Now it is assumed that 
inhibition of PPlase is central to the action of both FK 506 and cyclo-
spOIine, even though FK 506 has no biochemical relationship to cyclo-
sporine. What has happened here is that by accident a novel new class 
of cytosolic proteins (binding sites) has been discovered that is involved 
across a broad range of signal transduction processes that control the 
interior chemistry of the cell, not limited to immune modulation. This 
has been evident by studying the effects of the two PPlase inhibitors 
(cyclosporine and FK 506) on numerous physiologic processes, including 
carbohydrate, cholesterol, and uric acid metabolism; control of liver re-
generation (both drugs augment this process), neurologic functions, and 
hair growth, to supply an incomplete list. 
Finally, I want to pay tribute to Joel Cooper, the courageous Wash-
ington University surgeon who earlier today gave a classic paper on lung 
transplantation. The case he mentioned in discussing our paper is the 
first successful double lung retransplantation of which I am aware. It 
must have been a technical tour de force, and we were proud to help 
him from a distance. 
